Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.42 |
| ▸ | DRD3 | P35462 | 3/20 | 0.42 |
| ▸ | HTR1D | P28221 | 2/20 | 0.42 |
| ▸ | ADRB3 | P13945 | 10/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 8/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6133528 | 1.00 | DRD2 (0.42) | DRD2DRD3HTR1DADRB3ADRB1 | |
| SCHEMBL6133526 | 1.00 | DRD2 (0.42) | DRD2DRD3HTR1DADRB3ADRB1 | |
| SCHEMBL6134250 | 0.92 | DRD2 (0.43) | DRD2DRD3HTR1DADRB3ADRB1 | |
| SCHEMBL6134251 | 0.92 | DRD2 (0.43) | DRD2DRD3HTR1DADRB3ADRB1 | |
| SCHEMBL6134247 | 0.92 | DRD2 (0.43) | DRD2DRD3HTR1DADRB3ADRB1 | |
| SCHEMBL6135289 | 0.91 | ADRB3 (0.46) | ADRB3ADRB1 | |
| SCHEMBL6135293 | 0.91 | ADRB3 (0.46) | ADRB3ADRB1 | |
| SCHEMBL6135291 | 0.91 | ADRB3 (0.46) | ADRB3ADRB1 | |
| SCHEMBL6133680 | 0.90 | ADRB3 (0.45) | DRD2DRD3HTR1DADRB3ADRB1 | |
| SCHEMBL6133684 | 0.90 | ADRB3 (0.45) | DRD2DRD3HTR1DADRB3ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050090669-A1 | Aminoalcohol derivatives as beta-3 adrenergic receptor agonists | ASTELLAS PHARMA INC. (JP) | 2005-04-28 | — | — | US | disclosed |
| EP-1483236-A1 | AMINOALCOHOL DERIVATIVES AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-12-08 | — | — | EP | disclosed |
| WO-2003076397-A1 | AMINOALCOHOL DERIVATIVES AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090669-A1 | Aminoalcohol derivatives as beta-3 adrenergic receptor agonists | ADRB2, ADRB1, ADRB3 | DRD2 130/4885DRD3 113/4885HTR1D 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.